Spots Global Cancer Trial Database for A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
Official Title: A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases
Study ID: NCT00757757
Interventions
Study Description
Brief Summary: This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
NV Cancer Institute, Las Vegas, Nevada, United States
CTRC, San Antonio, Texas, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
